Strides Receives Us Fda Approval For Ursodiol Tablets

Strides Pharma Science Has Announced That Its Step-Down Wholly Owned Subsidiary, Strides Pharma Global Pte. Singapore, Has Received Approval For Ursodiol Tablets Usp, 250 Mg And 500 Mg From The United States Food &Amp; Drug Administration (Fda).The Product Is A Generic Version Of Urso, 250 Mg And Urso Forte Tablets 500 Mg, Of Allergan Sales, Llc.According To Iqvia Mat June 2020 Data, The Us Market For Ursodiol Tablets Usp, 250 Mg And 500 Mg Is Approximately Us$ 35 Million The Product Will Be Manufactured At The Company&Rsquo;S Flagship Facility At Bengaluru And Will Be Marketed By Strides Pharma Inc. In The Us Market.The Company Has 126 Cumulative Anda Filings With Us Fda Of Which 88 Andas Have Been Approved And 38 Are Pending Approval.Ursodiol Tablets Are Indicated For The Treatment Of Patients With Primary Biliary Cirrhosis (Pbc).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!